Therapeutic Advances in the Treatment of Gastroesophageal Cancers
Gastroesophageal cancers are a group of aggressive malignancies that are inherently heterogeneous with poor prognosis. Esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, and gastric adenocarcinoma all have distinct underlying molecular biology, w...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/13/5/796 |
| _version_ | 1827741912536186880 |
|---|---|
| author | Jenny J. Li Jane E. Rogers Kohei Yamashita Rebecca E. Waters Mariela Blum Murphy Jaffer A. Ajani |
| author_facet | Jenny J. Li Jane E. Rogers Kohei Yamashita Rebecca E. Waters Mariela Blum Murphy Jaffer A. Ajani |
| author_sort | Jenny J. Li |
| collection | DOAJ |
| description | Gastroesophageal cancers are a group of aggressive malignancies that are inherently heterogeneous with poor prognosis. Esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, and gastric adenocarcinoma all have distinct underlying molecular biology, which can impact available targets and treatment response. Multimodality therapy is needed in the localized setting and treatment decisions require multidisciplinary discussions. Systemic therapies for treatment of advanced/metastatic disease should be biomarker-driven, when appropriate. Current FDA approved treatments include HER2-targeted therapy, immunotherapy, and chemotherapy. However, novel therapeutic targets are under development and future treatments will be personalized based on molecular profiling. Herein, we review the current treatment approaches and discuss promising advances in targeted therapies for gastroesophageal cancers. |
| first_indexed | 2024-03-11T03:54:49Z |
| format | Article |
| id | doaj.art-8232fa4abe0a46b697c93242a952acef |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-11T03:54:49Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-8232fa4abe0a46b697c93242a952acef2023-11-18T00:39:19ZengMDPI AGBiomolecules2218-273X2023-05-0113579610.3390/biom13050796Therapeutic Advances in the Treatment of Gastroesophageal CancersJenny J. Li0Jane E. Rogers1Kohei Yamashita2Rebecca E. Waters3Mariela Blum Murphy4Jaffer A. Ajani5Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USADepartment of Pharmacy Clinical Program, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USADepartment of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USADepartment of Pathology, Division of Pathology/Lab Medicine, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USADepartment of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USADepartment of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USAGastroesophageal cancers are a group of aggressive malignancies that are inherently heterogeneous with poor prognosis. Esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, and gastric adenocarcinoma all have distinct underlying molecular biology, which can impact available targets and treatment response. Multimodality therapy is needed in the localized setting and treatment decisions require multidisciplinary discussions. Systemic therapies for treatment of advanced/metastatic disease should be biomarker-driven, when appropriate. Current FDA approved treatments include HER2-targeted therapy, immunotherapy, and chemotherapy. However, novel therapeutic targets are under development and future treatments will be personalized based on molecular profiling. Herein, we review the current treatment approaches and discuss promising advances in targeted therapies for gastroesophageal cancers.https://www.mdpi.com/2218-273X/13/5/796esophageal cancergastric cancerimmunotherapytargeted therapy |
| spellingShingle | Jenny J. Li Jane E. Rogers Kohei Yamashita Rebecca E. Waters Mariela Blum Murphy Jaffer A. Ajani Therapeutic Advances in the Treatment of Gastroesophageal Cancers Biomolecules esophageal cancer gastric cancer immunotherapy targeted therapy |
| title | Therapeutic Advances in the Treatment of Gastroesophageal Cancers |
| title_full | Therapeutic Advances in the Treatment of Gastroesophageal Cancers |
| title_fullStr | Therapeutic Advances in the Treatment of Gastroesophageal Cancers |
| title_full_unstemmed | Therapeutic Advances in the Treatment of Gastroesophageal Cancers |
| title_short | Therapeutic Advances in the Treatment of Gastroesophageal Cancers |
| title_sort | therapeutic advances in the treatment of gastroesophageal cancers |
| topic | esophageal cancer gastric cancer immunotherapy targeted therapy |
| url | https://www.mdpi.com/2218-273X/13/5/796 |
| work_keys_str_mv | AT jennyjli therapeuticadvancesinthetreatmentofgastroesophagealcancers AT janeerogers therapeuticadvancesinthetreatmentofgastroesophagealcancers AT koheiyamashita therapeuticadvancesinthetreatmentofgastroesophagealcancers AT rebeccaewaters therapeuticadvancesinthetreatmentofgastroesophagealcancers AT marielablummurphy therapeuticadvancesinthetreatmentofgastroesophagealcancers AT jafferaajani therapeuticadvancesinthetreatmentofgastroesophagealcancers |